CG Oncology (CGON) vs CRISPR Therapeutics (CRSP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
CG Oncology (CGON) has outperformed CRISPR Therapeutics (CRSP) over the past year, gaining 64.2% versus a loss of 34.3%. CG Oncology is the larger company by market cap ($5.61 billion vs $4.88 billion), about 1.1 times the size. CG Oncology converts more of its revenue into profit, with a net margin of -3985.0% versus -16569.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGON | CRSP |
|---|---|---|
| Share price | $63.26 | $50.44 |
| Market cap | $5.61B | $4.88B |
| 1-day change | +1.41% | -3.65% |
| YTD return | +50.24% | -3.81% |
| 1-year return | +64.16% | -34.31% |
| 5-year return | — | -48.00% |
| EPS (TTM) | $-2.69 | $-4.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.04M | $3.51M |
| Revenue growth (YoY) | +254.70% | -90.59% |
| Net income (latest FY) | $-161.00M | $-581.60M |
| Operating margin | -4722.13% | -18933.65% |
| Net margin | -3985.02% | -16569.77% |
| 52-week high | $80.97 | $78.38 |
| 52-week low | $35.80 | $44.12 |
| Distance from 52-week high | -21.87% | -35.65% |
| Analyst consensus | none | buy |
| Avg. price target upside | +43.98% | +73.59% |
| Average volume | 887.57K | 1.59M |
| Shares outstanding | 88.64M | 96.69M |
| Employees | 142 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CGON has outperformed CRSP by 98.5 percentage points over the past year.
- CG Oncology is more profitable, keeping -3985.0 cents of every revenue dollar as net income versus -16569.8 cents for CRISPR Therapeutics.
- CG Oncology grew revenue faster in its latest fiscal year (+254.70% vs -90.59%).
About CG Oncology
CGON stock →CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 142 employees
About CRISPR Therapeutics
CRSP stock →CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
CGON vs CRSP FAQ
Which is bigger, CG Oncology or CRISPR Therapeutics?
CG Oncology (CGON) is larger, with a market capitalization of $5.61B compared with $4.88B for CRISPR Therapeutics (CRSP).
Which stock has performed better over the past year, CGON or CRSP?
CGON returned +64.16% over the past 12 months, compared with -34.31% for CRSP (price return, excluding dividends). Past performance does not predict future results.
Are CG Oncology and CRISPR Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.